Bioequivalence of a Darunavir/Cobicistat Fixed-Dose Combination Tablet versus Single Agents and Food Effect in Healthy Volunteers

Abstract

Background

Darunavir requires pharmacokinetic enhancement to increase its bioavailability. Cobicistat is potentially an alternative pharmacokinetic booster to ritonavir. Bioequivalence of a darunavir/cobicistat fixed-dose combination (FDC) versus darunavir and cobicistat co-administered as single agents and the effect of a high-fat meal on the pharmacokinetics of the FDC were evaluated.

Methods

In this Phase I, open-label, randomized, three-panel, crossover study (NCT01619527), healthy volunteers received a single dose of darunavir (800 mg) with cobicistat (150 mg) as either an FDC or as single agents co-administered under fasted (panel 1, n=74) or fed (breakfast, panel 2, n=40) conditions, or as the FDC under fasted versus fed (high-fat breakfast) conditions (panel 3, n=19), with a ≥7 day washout period between treatments. Pharmacokinetic profiles, safety and tolerability were assessed.

Results

90% confidence intervals of the least square mean ratios for darunavir and cobicistat maximum plasma concentration and area under the plasma concentration–time curve (AUC) were all within 80.00% and 125.00% in panels 1 and 2. Administration of the FDC with a high-fat breakfast significantly increased darunavir maximum plasma concentration 2.27-fold and AUC 1.63–1.70-fold, whereas cobicistat pharmacokinetics were unaffected. No volunteers discontinued due to adverse events (AEs). All AEs were grade 1 or 2. Overall, 27 (20%) and 26 (20%) volunteers had ≥1 AE at least possibly related to darunavir and cobicistat, respectively.

Conclusions

Bioequivalence of the darunavir/cobicistat 800/150-mg FDC was demonstrated versus darunavir and cobicistat co-administered as single agents under fasted or fed conditions. Food increased darunavir exposure, therefore, darunavir/cobicistat should be administered with food.

References

DHHS guidelines: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1–239(Updated May 2014. Accessed 22 September 2014.) Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.

EACS. European AIDS Clinical Society Guidelines. (Updated June 2014. Accesssed 22 September 2014.) Available from http://www.eacsociety.org/Portals/0/140601_EACS%20EN7.02.pdf.

Thompson

M.A.

, Aberg

J.A.

, Hoy

J.F.

Antiretroviral treatment of adult HIV infection, 2012 recommendations of the International Antiviral Society-USA Panel. JAMA 2012; 308: 387–402.

Williams

, Churchill

, Anderson

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13 Suppl 2: 1–85.

Hull

M.W.

, Montaner

J.S.

Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med 2011; 43: 375–388.

Vermeir

, Lachau-Durand

, Mannens

Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos 2009; 37: 809–820.

Samaras

, Richardson

, Carr

Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected patients. AIDS 2010; 24: 1727–1731.

Foisy

M.M.

, Yakiwchuk

E.M.

, Hughes

C.A.

Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42: 1048–1059.

, Liu

, Murray

Cobicistat (GS-9350): a potent and selective inhibitor of human CYP 3A as a novel pharmacoenhancer. ACS Med Chem Lett 2010; 1: 209–213.

10.

Mathias

A.A.

, German

, Murray

B.P.

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther 2010; 87: 322–329.

11.

Lepist

E.I.

, Phan

T.K.

, Roy

Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother 2012; 56: 5409–5413.

12.

Shah

B.M.

, Schafer

J.J.

, Priano

, Squires

K.E.

Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2013; 33: 1107–1116.

13.

Lepist

, Zhang

, Hao

Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int 2014; 86: 350–357.

14.

Buscher

, Harman

, Kallen

M.A.

, Giordano

T.P.

Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients. Int J STD AIDS 2012; 23: 351–355.

15.

Juday

, Gupta

, Grimm

, Wagner

, Kim

Factors associated with complete adherence to HIV combination antiretroviral therapy. HIV Clin Trials 2011; 12: 71–78.

16.

Sterrantino

, Santoro

, Bartolozzi

, Trotta

, Zaccarelli

Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era. Patient Prefer Adherence 2012; 6: 427–433.

17.

Kauf

T.L.

, Davis

K.L.

, Earnshaw

S.R.

, Davis

E.A.

Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adherence 2012; 6: 155–164.

18.

Bangalore

, Kamalakkannan

, Parkar

, Messerli

F.H.

Fixed dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713–719.

19.

German

, Warren

, West

, Hui

, Kearney

B.P.

Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010; 55: 323–329.

20.

Ramanathan

, Warren

, Wei

, Kearney

B.P.

Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. 12–15 September 2009, San Francisco, CA, USA. Abstract A1-1301.

21.

Elion

, Cohen

, Gathe

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir DF in the initial treatment of HIV infection. AIDS 2011; 25: 1881–1886.

22.

Gallant

J.E.

, Koenig

, Andrade-Villanueva

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV type 1-infected patients: week 48 results. J Infect Dis 2013; 208: 32–39.

23.

Mathias

, Liu

H.C.

, Warren

, Sekar

, Kearney

B.P.

Relative bioavailability and pharmacokinetics of darunavir when boosted with the pharmacoenhancer GS-9350 versus RTV. 11th International Workshop on Clinical Pharmacology of HIV Therapy. 7–9 April 2010, Sorrento, Italy. Abstract 28.

24.

Kakuda

T.N.

, Opsomer

, Timmers

Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. J Clin Pharmacol 2014; 54: 949–957.

25.

Kakuda

T.N.

, Leopold

, Timmers

Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation. Int J Clin Pharmacol Ther 2014; 52: 805–816.

26.

Schöller-Gyüre

, Kakuda

R.N.

, Sekar

Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12: 789–796.

27.

DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 1.0. December 2004 (Updated August 2009. Accessed 19 June 2013.) Available from http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf.

28.

Boffito

, Miralles

, Hill

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients. HIV Clin Trials 2008; 9: 418–427.

29.

Sekar

, Vanden Abeele

, Van Baelen

Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir-ritonavir in the ARTEMIS study. 15th Conference on Retroviruses and Opportunistic Infections. 3–6 February 2008, Boston, MA, USA. Abstract 769.

30.

Sekar

, De La Rosa

, Van de Casteele

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial. 10th International Conference on Drug Therapy in HIV Infection. 7–11 November 2010, Glasgow, UK. Abstract P185.

31.

Kakuda

, Brochot

, Tomaka

Generalized additive model analysis of the relationship between darunavir pharmacokinetics and pharmacodynamics following once–daily darunavir/ritonavir 800/100mg treatment in the Phase III trials ARTEMIS and ODIN. 11th International Congress on Drug Therapy in HIV Infection. 11–15 November 2012, Glasgow, UK. Abstract P072.

32.

Connor

, Rafter

, Rodgers

Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ 2004; 82: 935–939.

33.

Sekar

, Kestens

, Spinosa-Guzman

The effect of different meal types on the pharmacokinetic of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol 2007; 47: 479–484.

34.

Cahn

, Fourie

, Grinzstein

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS 2011; 25: 929–939.

35.

Orkin

, DeJesus

, Khanlou

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med 2013; 14: 49–59.